BioSpace News Archive

First molecular glue program, BTX-1188, expected to enter the clinic by the end of 2021 Additional protein degradation programs on track for IND-enabling activities in 2022 Multi kinase inhibitor, BTX-A51, to continue in Phase 1 with expansion into solid tumors

Koya Medical , a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021 .

ITM to Host Virtual Symposium on “New Approaches for Targeted Radionuclide Therapy in Precision Oncology” with Key Opinion Leaders on Friday, June 4 th , 2021 in Parallel to 2021 ASCO Annual Meeting

-- Combined E1A and E4-ORF6/7 mutations demonstrate high degree of tumor selectivity in lead product candidate ICVB-1042 (formerly IOV-1042) -- -- IND filing for ICVB-1042 expected 1H 2022 -- -- Data published online in ASCO 2021 Annual Meeting Proceedings --

PBI-100 is a topical treatment being developed for people living with mild to moderate psoriasis PBI-100 is a highly-selective tropomyosin receptor kinase (TRK) inhibitor Psoriasis affects more than 120 million people worldwide, nearly eight million in US

- 12-month overall survival (OS) : 60% (n=6/10) in VBI-1901 + GM-CSF study arm compared to historical controls of ~30% 1 – 12-month OS not yet reached with VBI-1901 + AS01 B 2 - 6-month OS : 80%+ survival achieved across both study arms compared to historical controls of ~60% 1 - 2 partial tumor responses and 7 stable disease observations across both study arms - Full data to be highlighted in ASCO poster presentation June 4-8, 2021

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development, effective June 1, 2021. Mr. Arkowitz will report directly to Eric Shaff, President and Chief Executive Officer of Seres.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, announced today that management is scheduled to participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Friday, June 4, 2021 at 1:00 PM EDT.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the pricing of an underwritten public offering of 19,354,840 shares of its common stock, at a price to the public of $3.10 per share.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT.